Cryopreservation of umbilical cord mesenchymal cells in xenofree conditions

被引:36
作者
Prata, Karen de Lima [1 ,2 ]
de Santis, Gil Cunha [1 ,2 ]
Orellana, Maristela Delgado [1 ,2 ]
Bonini Palma, Patricia Vianna [1 ]
Brassesco, Maria Sol [3 ]
Covas, Dimas Tadeu [1 ,2 ]
机构
[1] Natl Inst Sci & Technol Stem Cell & Cell Therapy, Ctr Cell Therapy & Reg Blood Ctr, Ribeirao Preto, Brazil
[2] Univ Sao Paulo, Dept Internal Med, Sch Med, BR-14049 Ribeirao Preto, Brazil
[3] Univ Sao Paulo, Dept Pediat, Sch Med, BR-14049 Ribeirao Preto, Brazil
关键词
cryopreservation; DMSO; MSC; xenofree; THERAPY POSITION STATEMENT; MARROW STROMAL CELLS; STEM-CELLS; INTERNATIONAL-SOCIETY; GENE-EXPRESSION; TRANSPLANTATION; TISSUES; PROFILE;
D O I
10.3109/14653249.2012.677820
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background aims. Mesenchymal stromal cells (MSC) are being used to treat and prevent a variety of clinical conditions. To be readily available, MSC must be cryopreserved until infusion. However, the optimal cryopreservation methods, cryoprotector solutions and MSC sensitivity to dimethyl sulfoxide (DMSO) exposure are unknown. This study investigated these issues. Methods. MSC samples were obtained from human umbilical cord (n = 15), expanded with Minimal Essential Medium-alpha (alpha-MEM) 10% human serum (HS), resuspended in 25 mL solution (HS, 10% DMSO, 20% hydroxyethyl starch) and cryopreserved using the BioArchive (R) system. After a mean of 18 +/- 7 days, cell suspensions were thawed and diluted until a DMSO concentration of 2.5% was reached. Samples were tested for cell quantification and viability, immunophenotype and functional assays. Results. Post-thaw cell recovery: 114 +/- 2.90% (mean +/- SEM). Recovery of viable cells: 93.46 +/- 4.41%, 90.17 +/- 4.55% and 81.03 +/- 4.30% at 30 min, 120 min and 24 h post-thaw, respectively. Cell viability: 89.26 +/- 1.56%, 72.71 +/- 2.12%, 70.20 +/- 2.39% and 63.02 +/- 2.33% (P<0.0001) pre-cryopreservation and 30 min, 120 min and 24 h post-thaw, respectively. All post-thaw samples had cells that adhered to culture bottles. Post-thaw cell expansion was 4.18 +/- 0.17 X, with a doubling time of 38 +/- 1.69 h, and their capacity to inhibit peripheral blood mononuclear cells (PBMC) proliferation was similar to that observed before cryopreservation. Differentiation capacity, cell-surface marker profile and cytogenetics were not changed by the cryopreservation procedure. Conclusions. A method for cryopreservation of MSC in bags, in xenofree conditions, is described that facilitates their clinical use. The MSC functional and cytogenetic status and morphologic characteristics were not changed by cryopreservation. It was also demonstrated that MSC are relatively resistant to exposure to DMSO, but we recommend cell infusion as soon as possible.
引用
收藏
页码:694 / 700
页数:7
相关论文
共 18 条
[1]   Cryopreserved mesenchymal stromal cell treatment is safe and feasible for severe dilated ischemic cardiomyopathy [J].
Chin, Sze-Piaw ;
Poey, Alfred C. ;
Wong, Chee-Yin ;
Chang, Sau-Kong ;
Teh, William ;
Mohr, Teddric Jon ;
Cheong, Soon-Keng .
CYTOTHERAPY, 2010, 12 (01) :31-37
[2]   Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts [J].
Covas, Dimas T. ;
Panepucci, Rodrigo A. ;
Fontes, Aparecida M. ;
Silva, Wilson A., Jr. ;
Orellana, Maristela D. ;
Freitas, Marcela C. C. ;
Neder, Luciano ;
Santos, Anemari R. D. ;
Peres, Luiz C. ;
Jamur, Maria C. ;
Zago, Marco A. .
EXPERIMENTAL HEMATOLOGY, 2008, 36 (05) :642-654
[3]   Isolation and culture of umbilical vein mesenchymal stem cells [J].
Covas, DT ;
Siufi, JLC ;
Silva, ARL ;
Orellana, MD .
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2003, 36 (09) :1179-1183
[4]   Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement [J].
Dominici, M. ;
Le Blanc, K. ;
Mueller, I. ;
Slaper-Cortenbach, I. ;
Marini, F. C. ;
Krause, D. S. ;
Deans, R. J. ;
Keating, A. ;
Prockop, D. J. ;
Horwitz, E. M. .
CYTOTHERAPY, 2006, 8 (04) :315-317
[5]  
FRIEDENSTEIN AJ, 1966, J EMBRYOL EXP MORPH, V16, P381
[6]   Clarification of the nomenclature for MSC: The international society for cellular therapy position statement [J].
Horwitz, EM ;
Le Blanc, K ;
Dominici, M ;
Mueller, I ;
Slaper-Cortenbach, I ;
Marini, FC ;
Deans, RJ ;
Krause, DS ;
Keating, A .
CYTOTHERAPY, 2005, 7 (05) :393-395
[7]   Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells [J].
Le Blanc, K. ;
Samuelsson, H. ;
Gustafsson, B. ;
Remberger, M. ;
Sundberg, B. ;
Arvidson, J. ;
Ljungman, P. ;
Lonnies, H. ;
Nava, S. ;
Ringden, O. .
LEUKEMIA, 2007, 21 (08) :1733-1738
[8]   Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease:: a phase II study [J].
LeBlanc, Katarina ;
Frassoni, Francesco ;
Ball, Lynne ;
Locatelli, Franco ;
Roelofs, Helene ;
Lewis, Ian ;
Lanino, Edoardo ;
Sundberg, Berit ;
Bernardo, Maria Ester ;
Remberger, Mats ;
Dini, Giorgio ;
Egeler, R. Maarten ;
Bacigalupo, Andrea ;
Fibbe, Willem ;
Ringden, Olle .
LANCET, 2008, 371 (9624) :1579-1586
[9]   Hnmunomodulatory properties of mesenchymal stromal cells [J].
Nauta, Alma J. ;
Fibbe, Willem E. .
BLOOD, 2007, 110 (10) :3499-3506
[10]   Marrow stromal cells as steam cells for nonhematopoietic tissues [J].
Prockop, DJ .
SCIENCE, 1997, 276 (5309) :71-74